Gil Verschelden

601 total citations
8 papers, 109 citations indexed

About

Gil Verschelden is a scholar working on Infectious Diseases, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Gil Verschelden has authored 8 papers receiving a total of 109 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Infectious Diseases, 2 papers in Organic Chemistry and 2 papers in Molecular Biology. Recurrent topics in Gil Verschelden's work include Synthesis and biological activity (2 papers), Antibiotic Use and Resistance (2 papers) and Antibiotics Pharmacokinetics and Efficacy (2 papers). Gil Verschelden is often cited by papers focused on Synthesis and biological activity (2 papers), Antibiotic Use and Resistance (2 papers) and Antibiotics Pharmacokinetics and Efficacy (2 papers). Gil Verschelden collaborates with scholars based in Belgium, Germany and Canada. Gil Verschelden's co-authors include Amir Noeparast, Jacques De Grève, Sylvia De Brakeleer, Lore Decoster, Erik Teugels, Philippe Giron, Maya Hites, Johan Van Laethem, Cleo Goyvaerts and Ingrid Wybo and has published in prestigious journals such as Annals of Oncology, Frontiers in Microbiology and Oncotarget.

In The Last Decade

Gil Verschelden

8 papers receiving 108 citations

Peers

Gil Verschelden

MB

PRM

ONCOL

PFM

CR

Ruirui Ma China

Mohsen Malehmir Iran

Serdal Aktolga Türkiye

Yu Lan China

Xibin Zhuang China

Seyed Ali Mousavi‐Aghdas Iran

Manrose Singh United States

Facundo Vitelli‐Storelli Spain

F. M. Meng China

K. Dahm Germany

Ruirui Ma China

Gil Verschelden

101 ×1.7

MB

35 ×0.8

PRM

65 ×1.8

ONCOL

12 ×0.5

PFM

31 ×2.4

CR

Citations per year, relative to Gil Verschelden Gil Verschelden (= 1×) peers Ruirui Ma

Countries citing papers authored by Gil Verschelden

Since Specialization

Citations

This map shows the geographic impact of Gil Verschelden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gil Verschelden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gil Verschelden more than expected).

Fields of papers citing papers by Gil Verschelden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gil Verschelden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gil Verschelden. The network helps show where Gil Verschelden may publish in the future.

Co-authorship network of co-authors of Gil Verschelden

This figure shows the co-authorship network connecting the top 25 collaborators of Gil Verschelden. A scholar is included among the top collaborators of Gil Verschelden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gil Verschelden. Gil Verschelden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Mascart, Françoise, Maya Hites, Gil Verschelden, et al.. (2023). Analysis of a Combined HBHA and ESAT-6-Interferon-γ-Release Assay for the Diagnosis of Tuberculous Lymphadenopathies. Journal of Clinical Medicine. 12(6). 2127–2127. 2 indexed citations

2.

Verschelden, Gil, Amir Noeparast, Kristof Vandoorslaer, et al.. (2023). Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools. Frontiers in Microbiology. 14. 1322180–1322180. 8 indexed citations

3.

Verschelden, Gil, et al.. (2022). Optimization of the Transwell® assay for the analysis of neutrophil chemotaxis using flow cytometry to refine the clinical investigation of immunodeficient patients. Clinical Immunology. 238. 108994–108994. 2 indexed citations

4.

Verschelden, Gil, Amir Noeparast, Herman Goossens, et al.. (2021). Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study. International Immunopharmacology. 100. 108163–108163. 12 indexed citations

5.

Laethem, Johan Van, Lucie Seyler, Gil Verschelden, et al.. (2021). Presumed Urinary Tract Infection in Patients Admitted with COVID-19: Are We Treating Too Much?. Antibiotics. 10(12). 1493–1493. 7 indexed citations

6.

Verschelden, Gil, Johan Van Laethem, Brigitte Velkeniers, et al.. (2018). Significant response to dabrafenib in a patient with Erdheim–Chester disease with BRAFV600E mutation. Polskie Archiwum Medycyny Wewnętrznej. 128(6). 386–388. 5 indexed citations

7.

Noeparast, Amir, Erik Teugels, Philippe Giron, et al.. (2016). Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Oncotarget. 8(36). 60094–60108. 71 indexed citations

8.

Noeparast, Amir, Gil Verschelden, Ijeoma Adaku Umelo, et al.. (2015). Investigation of non-V600 BRAF mutations commonly found in NSCLC for their sensitivity to Dabrafenib or Trametinib. Annals of Oncology. 26. ii36–ii36. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact